Late-stage clinical biopharmaceutical firm Definium Therapeutics, Inc.
(NASDAQ:DFTX) has announced highly encouraging topline data from its Voyage trial.
The Phase 3 study evaluated the efficacy of DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults suffering from generalized anxiety disorder (GAD).
The Voyage trial successfully met its primary endpoint, demonstrating a clinically meaningful and statistically significant improvement over placebo.
The update marks the second successful Phase 3 readout for DT120 ODT, arriving shortly after the company reported positive Emerge trial data for major depressive disorder in June.
